The AJMC® Comprehensive Genomic Profiling compendium is a comprehensive resource for clinical news and expert insights for the next-generation sequencing approach to assess genes for the purpose of therapy guidance.
December 17th 2022
This American Academy of Dermatology (AAD) Annual Meeting covered a breakthrough therapy for the management of vitiligo, clinical and epidemiological differences of certain dermatologic diseases, and the role of dietary triggers on patient outcomes.
Liquid Biopsy of Cerebrospinal Fluid May Improve Treatment Considerations in NSCLC
October 22nd 2021Study findings suggest that the unique genomic variations of cerebrospinal fluid can be leveraged as a liquid biopsy to effectively and safely improve decision-making regarding treatment of patients with non–small cell lung cancer (NSCLC) with leptomeningeal metastasis.
Read More
Reimbursement for Genetic Variant Reinterpretation: Five Questions Payers Should Ask
Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.
Read More
The Myriad Ways ctDNA Analysis Using Liquid Biopsy Can Be Applied in NSCLC
October 5th 2021A literature review examined the many clinical applications for circulating tumor DNA (ctDNA) analysis in non–small cell lung cancer (NSCLC) and provided insight into how liquid biopsy can help avoid certain limitations presented by other ctDNA analysis methods.
Read More
Comprehensive Genomic Features, Therapeutic Biomarkers Identified in Clear Cell Renal Cell Carcinoma
October 1st 2021Investigators reported comprehensive genomic features of patients with clear cell renal cell carcinoma, potentially giving providers a better understanding of the molecular features associated with the disease.
Read More
Polymerase chain reaction–based comprehensive genomic profiling testing provided useful information for more than 94% of samples, including 81% of samples that normally would not have been tested, suggesting that more patients may benefit from CGP testing than anticipated.
Read More
The Role of Liquid Biopsy in Determining Prognosis, Treatment in Surgical Oncology
September 15th 2021A literature review detailed the multitude of ways that liquid biopsy can be used to aid the treatment of patients with cancer, including aiding in screening, recurrence surveillance, genomic profiling, and therapeutic decision-making.
Read More
Prognostic Biomarkers Identified for Pancreatic Ductal Adenocarcinoma Using Whole Genome Sequencing
September 11th 2021Investigators identified 5 mutated genes that could serve as biomarkers for disease prognosis and clinical outcomes associated with pancreatic ductal adenocarcinoma, a common cancer with a high mortality rate and poor prognosis.
Read More
Study: Serial Liquid Biopsy May Be Useful in Identifying RAS Genetic Mutations in mCRC
September 3rd 2021Investigators identified serial liquid biopsy as an effective tool for identifying mutational changes of RAS genes in patients with metastatic colorectal cancer (mCRC) who have undergone antiangiogenic therapy.
Read More
Copy Number Signatures Predict Chromothripsis, Prognosis in Newly Diagnosed MM
September 2nd 2021Using whole genome sequencing, copy number signatures were successful in predicting both the presence of chromothripsis and clinical outcomes in patients with newly diagnosed multiple myeloma (MM).
Read More
Foundation Medicine, Epic Partner on Access to Genomic Profiling in EHRs
August 26th 2021Foundation Medicine and Epic struck a deal to integrate comprehensive genomic profiling within Epic's electronic health records (EHRs), allowing for providers to order and review genomic profiling tests, leading to more streamlined clinical decision making.
Read More
Study Finds Individuals Carry Genetic Variants for Actionable Monogenic Disorders
August 25th 2021Approximately 1 in 6 healthy individuals who underwent proactive genetic screening had genetic variants linked to increased risk for developing medically actionable disorders, including certain cancers and cardiovascular disorders.
Read More
Review Outlines Potential Benefits, Challenges of Next-Generation Sequencing for Early-Stage NSCLC
August 18th 2021Investigators examined the current bodies of evidence surrounding the emergence of next-generation gene sequencing, and the challenges that come with it, for identifying oncogenic drivers of early-stage non–small cell lung cancer (NSCLC).
Read More
Impact of Expanded Carrier Screening on Health Care Utilization
This study shows little evidence of harms or increased health care utilization for people receiving negative (normal) results of expanded carrier screening through genome sequencing.
Read More
Study Explores Why People Refuse to Hear About Secondary Genetic Findings
August 11th 2021Fear of negative emotions, lack of interest, and distrust of medical institutions were some of the reasons that participants refused to receive information regarding medically actionable secondary genetic findings, even after they received additional education on what the findings would include.
Read More